PRKN and cancer: The impairment of mitochondrial function via interfering certain signalling pathways, such as mTOR and CaMKII/Parkin/mitophagy, was targeted by several studies to tackle metabolic stress in CC cell lines, to inhibit the cancer cell growth [70–72].